Key Determinants in the Occurrence of Clonal Variation in Humanized Antibody Expression of CHO Cells during Dihydrofolate Reductase Mediated Gene Amplification
The DOI matches its Crossref record.
Abstract
Recombinant Chinese hamster ovary (CHO) parental clones expressing a humanized antibody against S surface antigen of hepatitis B virus were obtained by cotransfection of heavy chain (HC) and light chain (LC) cDNA expression vectors into dihydrofolate reductase (DHFR)-deficient CHO cells. When 23 representative parental clones were subjected to stepwise selection for increasing methotrexate (MTX) resistance, such as 0.02, 0.08, 0.32, and 1.0 microM, their clonal variations in regard to antibody expression were found to be significant. Among 23 parental clones, only one clone (hu17) showed the significant increment of specific antibody productivity (q(Ab)) with increasing MTX concentration up to 0.32 microM. Compared with the parental clone (hu17), the q(Ab) of hu17 resistant at 0.32 microM MTX (hu17-0.32) was enhanced approximately 12.5-fold. To clarify the reason for the occurrence of clonal variations, Southern blot analyses of chromosomal DNAs derived from each amplified clone at 0.32 microM MTX were performed. Only the hu17-0.32 clone did not experience severe genetic rearrangement during gene amplification, and it had only one 49-kb amplification unit including the LC and HC cDNAs. A fluorescent MTX competition assay showed that the resistance against MTX toxicity of the other clones without enhanced q(Ab) at 0.32 microM MTX was obtained by mechanisms such as an impaired MTX transport system. Taken together, the data obtained here show that clonal variations in regard to antibody expression are found to be significant because clones can acquire MTX resistance by mechanisms other than DHFR-mediated gene amplification despite the stepwise selection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Advances in Mammalian cell line development technologies for recombinant protein production
Lai, T., Yang, Y., & Ng, S. (2013) · Pharmaceuticals · doi:10.3390/ph6050579 · Cited by 322
“Another reason for cloning the cells is that high producing clones occur rarely in the heterogeneous cell populations after transfection and gene amplification [24–28].”
BackgroundA study of monoclonal antibody‐producing CHO cell lines: What makes a stable high producer?
Chusainow, J., Yang, Y. S., Yeo, J. H. M., Toh, P. C., Asvadi, P., Wong, N. S. C., & Yap, M. G. S. (2009) · Biotechnology and Bioengineering · doi:10.1002/bit.22158 · Cited by 313
Ghorbaniaghdam, A., Chen, J., Henry, O., & Jolicoeur, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090832 · Cited by 71
Using matrix attachment regions to improve recombinant protein production
Harraghy, N., Buceta, M., Regamey, A., Girod, P.-A., & Mermod, N. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-352-3_7 · Cited by 30
Kim, T. K., Chung, J. Y., Sung, Y. H., & Lee, G. M. (2001) · Biotechnology and Bioprocess Engineering · doi:10.1007/bf02933001 · Cited by 28
“When recombinant CHO (rCHO) cell clones have been subjected to successive rounds of selection in media that contain stepwise increments of MTX concentrations, it has been found that the specific productivity (q) does not always increase linearly by increasing the MTX dosage and the enhancement of q varies signi fycant…”
BackgroundSelf-citation
Metadata
- Authors
- Kim, N. S., Byun, T. H., & Lee, G. M.
- Venue
- Biotechnology Progress
- Publisher
- Wiley
- Published
- 2001-02-02
- Volume
- 17
- Issue
- 1
- Pages
- 69-75
- ISSN
- 1520-6033 (ISSN-L)
- 8756-7938
- OpenAlex
- W2010405617
- Cited by
- 62
- References
- 0
- FWCI
- 0.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Key Determinants in the Occurrence of Clonal Variation in Humanized Antibody Expression of CHO Cells during Dihydrofolate Reductase Mediated Gene Amplification. https://app.cochat.ai/papers/10.1021/bp000144h
- The paper
- Kim, N. S., Byun, T. H., & Lee, G. M. (2001). Key Determinants in the Occurrence of Clonal Variation in Humanized Antibody Expression of CHO Cells during Dihydrofolate Reductase Mediated Gene Amplification. Biotechnology Progress. https://doi.org/10.1021/bp000144h
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.